×
Mirum Pharmaceuticals Inventory 2019-2024 | MIRM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Mirum Pharmaceuticals inventory from 2019 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
View More
Mirum Pharmaceuticals Inventory 2019-2024 | MIRM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Mirum Pharmaceuticals inventory from 2019 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$170.3B
Vertex Pharmaceuticals (VRTX)
$122B
Bristol Myers Squibb (BMY)
$112.5B
Gilead Sciences (GILD)
$111.9B
Regeneron Pharmaceuticals (REGN)
$91.4B
CSL (CSLLY)
$90.8B
GSK (GSK)
$76.6B
Argenex SE (ARGX)
$35.2B
Alnylam Pharmaceuticals (ALNY)
$34.8B
BioNTech SE (BNTX)
$25.9B
Biogen (BIIB)
$25.3B
Illumina (ILMN)
$24.5B
Moderna (MRNA)
$20.6B
BeiGene (BGNE)
$20.2B
Genmab (GMAB)
$15.1B
Incyte (INCY)
$14.6B
Exact Sciences (EXAS)
$13.1B
BioMarin Pharmaceutical (BMRN)
$12.6B
Insmed (INSM)
$12.2B
Bio-Techne Corp (TECH)
$12B
Vaxcyte (PCVX)
$11.9B
Sarepta Therapeutics (SRPT)
$11.7B
QIAGEN (QGEN)
$10B
Exelixis (EXEL)
$9.8B
Bio-Rad Laboratories (BIO.B)
$9.3B
Revolution Medicines (RVMD)
$9.3B
Intra-Cellular Therapies (ITCI)
$9.1B
Roivant Sciences (ROIV)
$8.5B
Legend Biotech (LEGN)
$8B
Repligen (RGEN)
$7.8B